EUVIMEDEUVIMED entdecken
Fallbericht

Onasemnogene Abeparvovec is Safe in Hemolytic Disease of the Newborn: A Case Report

Momen Almomen iD, Maher El Doussouki, Shaikhah Aldossary, Tasneem Atawi

Neuropediatrics · 01.06.2025 · 56 (03) · 200-203

DOI: 10.1055/a-2491-2141 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Neuropediatrics, erschienen am 01.06.2025. Verfasst von Momen Almomen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Neurology, Neuroscience Center, King Fahd Specialist Hospital, Dammam, Saudi Arabia. Hauptthemen laut MEDLINE: Biological Products, Erythroblastosis, Fetal. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spinal muscular atrophy (SMA) is a rare autosomal recessive genetic disease caused by Survival Motor Protein 1 (SMN1) gene mutations. Classically divided into three types, SMA is characterized by hypotonia, weakness, and tongue fasciculation in the first 6 months of life in type 1, inability to walk and limb weakness in type 2, and failure to run with proximal weakness in type 3 SMA. With the advent of newborn screening, treating presymptomatic patients with Onasemnogene abeparvovec (OA) is the treatment of choice in some centers worldwide. The incidence of jaundice is high in this age group, with no recommendation to guide the use of OA in newborns with jaundice. To our knowledge, treating an SMA patient with alloimmune hemolytic disease of the newborn (HDN), a relatively common disease in the newborn period, has never been reported in the past. We report our experience with dosing a presymptomatic child with SMA who had neonatal jaundice and hemolytic anemia due to hemolytic disease of the newborn who tolerated the treatment well. To our knowledge, this is the first case to report the safety of this novel treatment for an SMA patient with alloimmune HDN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsErythroblastosis, FetalHumansInfant, NewbornMaleFemaleRecombinant Fusion Proteins

Substanzen

Biological ProductsZolgensmaRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Pediatric Neurology, Neuroscience Center, King Fahd Specialist Hospital, Dammam, Saudi Arabia.
  • Department of Hematology-Oncology and Stem Cell Transplantation, King Fahd Specialist Hospital, Dammam, Saudi Arabia.
  • Department of Physiotherapy, King Fahd Specialist Hospital, Dammam, Saudi Arabia.

ORCID-Profile: Momen Almomen

Zitieren

APA

Almomen, M., El Doussouki, M., Aldossary, S., & Atawi, T. (2025). Onasemnogene Abeparvovec is Safe in Hemolytic Disease of the Newborn: A Case Report. Neuropediatrics, 56(03), 200-203. https://doi.org/10.1055/a-2491-2141

Vancouver

Almomen M, El Doussouki M, Aldossary S, Atawi T. Onasemnogene Abeparvovec is Safe in Hemolytic Disease of the Newborn: A Case Report. Neuropediatrics. 2025;56(03):200-203. doi:10.1055/a-2491-2141

BibTeX
@article{Almomen2025,
  author = {Almomen, Momen and El Doussouki, Maher and Aldossary, Shaikhah and Atawi, Tasneem},
  title = {Onasemnogene Abeparvovec is Safe in Hemolytic Disease of the Newborn: A Case Report},
  journal = {Neuropediatrics},
  year = {2025},
  volume = {56},
  number = {03},
  pages = {200--203},
  doi = {10.1055/a-2491-2141}
}
Kostenlos starten →